Halozyme Therapeutics, Inc.
Get Full AccessDescription
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
-
Headquarters:11388 Sorrento Valley Road , San Diego, California, United States
More -
Phone Number: +1 858-794-8889
-
Website: http://www.halozyme.com/
-
Employees:271
-
Revenue:$250 - 500M
-
Legal Name:Halozyme Therapeutics, Inc.
-
Halozyme Therapeutics, Inc.'s Social Media
-
Is this data correct?
-
| NAICS Code: 423450 |
NYSE: HALO
Show More
Sell more in less time!
Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!
Frequently Asked Questions regarding Halozyme Therapeutics, Inc.
-
Where are Halozyme Therapeutics, Inc.'s Headquarters?
Halozyme Therapeutics, Inc.'s Headquarters are in 11388 Sorrento Valley Road ,San Diego,California,United States
-
What is Halozyme Therapeutics, Inc.'s phone number?
Halozyme Therapeutics, Inc.'s phone number is +1 858-794-8889
-
What is Halozyme Therapeutics, Inc.'s stock symbol?
Halozyme Therapeutics, Inc.'s stock symbol is HALO
-
What is Halozyme Therapeutics, Inc.'s official website?
Halozyme Therapeutics, Inc.'s official website is http://www.halozyme.com/
-
What is Halozyme Therapeutics, Inc.'s Revenue?
Halozyme Therapeutics, Inc.'s revenue is $250 - 500M
-
What is Halozyme Therapeutics, Inc.'s NAICS code?
Halozyme Therapeutics, Inc.'s NAICS code is 423450
-
How many employees are working in Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. has 271 employees
-
What is Halozyme Therapeutics, Inc.'s Industry?
Halozyme Therapeutics, Inc. is in the industry of Biotechnology